Lupin Net Profit Rises 35pc to Rs 390 crore in Q4
Lupin had posted a net profit of Rs 289.56 crore for the corresponding period of the previous fiscal.
Mumbai: Drug firm Lupin has reported a 34.55 percent rise in its consolidated net profit to Rs 389.63 crore for the quarter ended March 2020 mainly on account of robust sales in the domestic market and lower tax expenses. The company had posted a net profit of Rs 289.56 crore for the corresponding period of the previous fiscal, Lupin said in a late-night filing on Thursday.
Consolidated income from operations of the company stood at Rs 3,791 crore for the quarter under consideration as against Rs 3,807.02 crore for the same period year ago.
Consolidated income from operations of the company stood at Rs 3,791 crore for the quarter under consideration as against Rs 3,807.02 crore for the same period year ago.
The company's income from operations for the fiscal year ended March this year stood at Rs 15,142.80 crore. It was Rs 14,318.05 crore for the year-ago fiscal.
The net debt as on March 31, 2020, stood at Rs 1,511.8 crore. The net debt-equity ratio for the company was at 0.12:1 as on March 31, 2020, Lupin said.
"We closed the year with strong growth across all our key markets and significant strengthening of our profitability and balance sheet. We have had strong momentum in our two major markets, the US and India, and on compliance across our facilities," Lupin MD Nilesh Gupta said.
Importantly, in the current times, Lupin has been able to ensure business continuity while safeguarding the health and safety of its employees, he added.
During the quarter under consideration, India region formulation sales grew by 15 percent compared to the same quarter in the year-ago fiscal year.
The total tax expense of the company for the fourth quarter of FY 2020 was at Rs 105.07 crore as against Rs 294.27 crore for the same period year ago, it added.
Also Read: Lupin Gets USFDA Nod For Trientine Hydrochloride Capsules
Investment in research and development for continued operations amounted to Rs 1,553.8 crore (10.3 percent of sales) for FY2020 and Rs 344.2 crore (9.1 percent of sales) for Q4 FY2020, the filing said.
The board of directors of the company has recommended a dividend of Rs 6 per equity share of the face value of Rs 2 each aggregating to Rs 271.84 crore, Lupin said.
Also Read: Lupin Launches Generic Apriso In US
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.